The World Health Organization released new findings on Friday about an "alarming" lack of awareness about alcohol's link to ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Many consumer devices undergo the FDA clearance process, such as LED masks and fitness trackers that have features like ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

The Hawaii Emergency Management Agency plans for and responds to both natural and human-caused emergencies. Because of the storm, the Emergency Operations Center was activated. It may be new to ...

The Hawaii Emergency Management Agency plans for and responds to both natural and human-caused emergencies. Because of the storm, the Emergency Operations Center was activated.

The European Open is set for a relocation in 2025. The mega-event has been organised for nine years in Antwerp, but as per the latest report, it will now move to Brussels in 2025. The development was ...

Many products require CE marking before they can be sold in the EU. CE marking indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental ...

Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...